| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Yi-Nan Ding, Ming Xue, Qiu-Sha Tang, Li-Jun Wang, Hui-Yan Ding, Han Li, Cheng-Cheng Gao and Wei-Ping Yu |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| National Natural Science Foundation of China |
82102303 |
| Natural Science Foundation of Jiangsu Province, China |
BK20210231 |
|
| Corresponding Author |
Wei-Ping Yu, MD, PhD, Doctor, Doctor, Professor, Medical School, Southeast University, No. 87 Dingjiaqiao, Nanjing 210009, Jiangsu Province, China. wpylg@hotmail.com |
| Key Words |
Gastrointestinal cancer; Gastric cancer; Hepatocellular carcinoma; Colorectal cancer; Pancreatic cancer; Immunotherapy-based novel nanoparticles |
| Core Tip |
Recently, immunotherapy has received substantial attention. Although there are several Food and Drug Administration-approved immune checkpoint blockade (ICB) drugs, the efficacy remains limited, and the response rate is less than 20%. Because gastrointestinal cancer (GIC) is a group of immunosuppressive cancers, the efficacy of ICB treatment is also limited. Therefore, enhancing the immunogenicity of GIC or reversing the immunosuppressive microenvironment of GIC have become potential approaches for GIC immunotherapy. There are many studies on nanoparticle-based cancer therapy. However, there are only a few studies on immunotherapy-based nanoparticles in GIC. Here, we summarize recent advances in the application of immunotherapy-based nanoparticles in GIC and present our thoughts about this topic. |
| Publish Date |
2022-09-29 10:42 |
| Citation |
Ding YN, Xue M, Tang QS, Wang LJ, Ding HY, Li H, Gao CC, Yu WP. Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: Trends and challenges. World J Gastroenterol 2022; 28(37): 5403-5419 |
| URL |
https://www.wjgnet.com/1007-9327/full/v28/i37/5403.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v28.i37.5403 |
